Patient Gateway

RSS Feed

An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C–IV non-squamous NSCLC

Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis

Akeso and Summit’s ivonescimab meets OS goals in NSCLC

ctDNA-based detection of residual disease: implications for management of non-metastatic NSCLC

SANOVO: Osimertinib Plus Savolitinib Moves MET-Directed Therapy Into First-Line EGFR-Mutated NSCLC

陈显教授：HER2 突变 NSCLC 脑转移治疗新格局--从前瞻性注册研究到真实世界证据的双重验证_腾讯新闻

HUTCHMED Reports Positive Phase 3 SANOVO Results for Savolitinib Plus Osimertinib in EGFR-Mutated NSCLC

Savolitinib Combo Boosts PFS in First-Line EGFR-Mutant NSCLC Trial

Hutchmed (00013) announced that the SANOVO study of the combination therapy of ORPATHYS and TAGRISSO demonstrated a significant progression-free survival benefit in previously untreated Chinese patients with EGFR-mutated non-small cell lung cancer (NSCLC)